Indian pharma's risk aversion holding back innovation: Kiran Mazumdar-Shaw
Benchmarks Nifty22,622.70-99.25FEATURED FUNDS★★★★★UTI Aggressive Hybrid Fund Regular Plan-Growth5Y Return8.71 % Invest NowFEATURED FUNDS★★★★★Motilal Oswal Midcap Fund Direct-Growth5Y Return19.29 % Invest NowEnter search…
Biocon chairperson Kiran Mazumdar-Shaw calls for greater use of digital technology to speed up drug development, as industry leaders push for a shift beyond generics.
Listen to this article in summarized format
Loading...×New Delhi: Indian pharmaceutical industry's aversion to taking risks poses a major hurdle for innovation and that needs to change with the use of technology, according to Biocon chairperson Kiran Mazumdar-Shaw."In pharma and biopharma, the pipeline is the lifeline," Mazumdar-Shaw said at a meeting on quality management in New Delhi last week, stressing the need to replenish the drug development pipeline continuously.
Drug discovery is fraught with risks, with only one or two out of 10 candidates advancing to the final stages and meeting commercial milestones.
Mazumdar-Shaw was part of a panel that included Sun Pharma executive chairman Dilip Shanghvi and Glenmark Pharma chairman Glenn Saldanha. The three industry leaders discussed the sector's future direction and India's shift from a long history of generic drugs towards innovative medicines.
Indian Foundation of Quality Management, a consortium of companies, including Tata Sons, TVS Motors, Biocon, Sun Pharma, Boeing and Motherson, organised the two-day event.
Live Events
Mazumdar-Shaw said Biocon had advanced an anti-cancer drug to Phase III clinical trials. She added that India's regulatory process was gaining momentum.
"We made slow progress in aligning and now it looks positive. It is time to leapfrog with the help of digital technology. We should deep dive and emulate not just China but also countries like Australia to move molecules rapidly into the clinic and beyond," she said. Mazumdar-Shaw said most Indian companies conduct animal studies abroad and that this needed to change.
Shanghvi, whose Sun Pharma agreed to buy US-based Organon for a record $11.75 billion earlier this year, said generic drugs account for a large share of global pharmaceutical sales by volume but only 20% by value.
"If we want to succeed and become big globally and help patients, our focus on innovation is needed and that I think should be the priority. It also ties with Prime Minister Narendra Modi's objective of Viksit Bharat by 2047," he said.
Indian pharmaceutical companies broadly fall into three categories: generics, generics and biosimilars, and innovation-led businesses, Saldanha said. Building scale in innovation through deals or licensing is important, he added.
"We need a continuous pipeline, and we should see a lot in the next five to 10 years," he said.
Shanghvi said the acquisition of Organon could help Sun Pharma launch innovative products globally. "In Europe, China, Korea, Taiwan, Australia, Turkey and many other countries, we lost time in registering (of products) and in countries like Brazil and Mexico, we did not have the infrastructure. Organon gives us the ability, and it also gives us a higher share of innovative drugs," he said.
Organon also gives Sun Pharma the familiarity needed to manage innovation faster, Shanghvi said.
Add as a Reliable and Trusted News Source Add Now!
(You can now subscribe to our Economic Times WhatsApp channel)
Read More News onsun pharmabioconIndian pharmaceutical industrybiopharma innovationsSun Pharma acquisitionbioconglenmark pharmatvs motors
(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)
...moreless(You can now subscribe to our Economic Times WhatsApp channel)
Read More News onsun pharmabioconIndian pharmaceutical industrybiopharma innovationsSun Pharma acquisitionbioconglenmark pharmatvs motors
(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)
...morelessContinue reading with one of these options:Limited AccessFreeLogin to get access to some exclusive stories& personalised newslettersLogin NowUnlimited AccessStarting @ Rs120/monthGet access to exclusive stories, expert opinions &
in-depth stock reportsSubscribe NowET
Unlock Access to All Exclusives with ETPrime FREE TRIAL
15 Days Free: Unlock All ETPrime Exclusives, Market Tools & ePapers
Trial offer expiring in00 : 05 : 00
I'd rather pay ₹2599 nowUh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
Prime Account Detected!
It seems like you're already an ETPrime member with
Login using your ET Prime credentials to enjoy all member benefits
Log out of your current logged-in account and log in again using your ET Prime credentials to enjoy all member benefits.
Unlock ETPrime's Exclusive Stories Today!
Big Price Drop! Flat 40% Off
Student Only OfferAlready a Member? Sign In nowAlready a Member? Sign In nowAlready a Member? Sign In nowOffer Exclusively For You
Save up to Rs. 700/-
ON ET PRIME MEMBERSHIP
Avail OfferOffer Exclusively For You
Get 1 Year Free
With 1 and 2-Year ET prime membership
Avail OfferOffer Exclusively For You
Get 1 Year Free
With 1 and 2-Year ET prime membership
Avail OfferOffer Exclusively For You
Get Flat 40% Off
Then ₹ 1749 for 1 year
Avail OfferOffer Exclusively For You
ET Prime at ₹ 49 for 1 month
Then ₹ 1749 for 1 year
Avail OfferSpecial Offer
Get flat 40% off on ETPrime
Avail OfferAvail OfferClaim NowAlready a Member? Sign In nowNeed Assistance?
Connect with an ETPrime expert for personalized support and guidance
+91 9484700004'; }); } if(listing) { var h3 = "You tried reading " + listArr.length + " locked stories in the past " + threshold + " days.", h4 = "Become an ET Prime member and don't miss out on these exclusive stories."; var html = '' + h3 + '
' + h4 + '
- ' + listing + '
What’s Included with
ETPrime Membership
1Exclusive Insights That Matter
Uncover the truth with our investigative stories
Make strategic moves using the real-world case studies
Read industry-specific stories to identify emerging trends
Spot opportunities with in-depth insights that matter
Trump temper on H-1B visas is forcing Indians to do these things to stay put in US
What Adani’s US indictment means for India Inc’s overseas fundraising
Why veterans like Reliance, L&T are on acquisition spree? Aswath Damodaran has an answer.
Will China’s dollar bond sale in Saudi Arabia trump the US in financial world?
Huawei launches its own OS to compete with Google and Apple. But can it win beyond China?
The problem with lab grown diamonds
Why a falling rupee is a better option for the economy
A list of top 20 momentum stocks that have delivered massive returns in one year
2Invest Wisely With Smart Market Tools & Investment Ideas
Alpha Trade
Get daily trade ideas from SEBI-registered research analysts.
Investment Ideas
Grow your wealth with stock ideas & sectoral trends.
Stock Reports Plus
All-in-one stock research with Stock Score, peer comparison & key signals.
BigBull Portfolio
Get to know where the market bulls are investing to identify the right stocks.
Stock Analyzer
Check the score based on the company's fundamentals, solvency, growth, risk & ownership to decide the right stocks.
Market Mood
Analyze the market sentiments & identify the trend reversal for strategic decisions.
Stock Talk Live at 9 AM Daily
Ask your stock queries & get assured replies by ET appointed, SEBI registered experts.
3Stay informed anytime, anywhere with ET ePaper
ePaper - Print View
Read the PDF version of ET newspaper. Download & access it offline anytime.
ePaper - Digital View
Read your daily newspaper in Digital View & get it delivered to your inbox everyday.
Wealth Edition
Manage your money efficiently with this weekly money management guide.
TOI ePaper
Read the PDF version of TOI newspaper. Download & access it offline anytime.
Deep Explainers
Explore the In-depth explanation of complex topics for everyday life decisions.
Health+ Stories
Get fitter with daily health insights committed to your well-being.
Personal Finance+ Stories
Manage your wealth better with in-depth insights & updates on finance.
5Enjoy Complimentary Subscriptions From Top Brands
Stream new documentaries from all across the world every day.
Stories you might be interested in
Figures reflect the source report and its stated period. This article is for information and is not investment advice.
